Investing.com -- Jefferies upgraded German solar inverter manufacturer SMA Solar to “buy” from “hold” and raised its price target to €39 from €22, citing improved profitability prospects driven by ...

There are many ways products can aid installation in the residential market, whether it’s software that makes designing easier or mounting systems with fewer parts to assemble. For the 2024 Top ...

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...

Novartis ( NVS) on Monday said that the U.S. FDA has approved Itvisma for the treatment of children two years and older, ...

Onasemnogene abeparvovec-brve is the first gene replacement therapy approved for SMA patients aged 2 years and older, expanding access beyond infants. Phase 3 trials demonstrated significant motor ...

The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...

The global solar inverter market was valued at US$12.81 billion in 2023 and is forecasted to reach US$24.40 billion by 2029, with a CAGR of 11.34% from 2024-2029. Solar inverters are crucial for ...

The approval is supported by findings from the open-label Phase IIIb STRENGTH study and the Phase III STEER study.

Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and older, teens, and adults with spinal muscular atrophy (SMA). The therapy ...

The U.S. Food and Drug Administration has approved Itvisma as the first gene therapy for spinal muscular atrophy patients ...

Looking to buy an Luminous inverter? Here’s a database of the latest models from the company, along with useful filters and sorting tools to let you find the most suitable one for you. With the help ...